

# Reference list

ANTIBIOTIC RESISTANCE: THE SILENT TSUNAMI

## Part 3

### Nearly empty pipeline

Silver LL. Challenges of antibacterial discovery. *Clin Microbiol Rev.* 2011 Jan;24(1):71–109.

### Why don't we simply develop new antibiotics?

Bush K. Investigational Agents for the Treatment of Gram-Negative Bacterial Infections: A Reality Check. *ACS Infect. Dis.* 2015 Oct;1(11):509-511.

Cooper MA, Shlaes D. Fix the antibiotics pipeline. *Nature.* 2011 Apr;472(7341):32.

Fischbach MA, Walsh TW. Antibiotics for Emerging Pathogens. *Science.* 2009 Aug;325(5944):1089-1093.

Hughes D, Karlén A. Discovery and preclinical development of new antibiotics. *Ups J Med Sci.* 2014 May;119(2):162-169.

Page MG, Bush K. Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising? *Curr Opin Pharmacol.* 2014 Oct;18:91-7.

Payne DJ, Gwynn MN, Holmes DJ, Pogliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. *Nat Rev Drug Discov.* 2007 Jan;6(1):29-40.

### Alternatives to antibiotics

Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. *Nat Rev Microbiol.* 2004 Sep;2(9):695-703.

Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock RE, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, Ólafsdóttir S, Payne D, Projan S, Shaunak S, Silverman J, Thomas CM, Trust TJ, Warn P23, Rex JH. Alternatives to antibiotics—a pipeline portfolio review. *Lancet Infect Dis.* 2016 Feb;16(2):239-51.

Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen JA, Klugman K, Davies S. Access to effective antimicrobials: a worldwide challenge. *Lancet.* 2016 Jan 9;387(10014):168-75.

Loc-Carrillo C., Abedon S.T. Pros and cons of phage therapy. *Bacteriophage.* 2011 Mar;1(2):111-114.

Review on Antimicrobial Resistance (AMR Review). Vaccines and alternative approaches: reducing our dependence on antimicrobials. The Review on Antimicrobial Resistance, chaired by Jim O'Neill. 2016 Feb. Available at: [https://amr-review.org/sites/default/files/Vaccines%20and%20alternatives\\_v4\\_LR.pdf](https://amr-review.org/sites/default/files/Vaccines%20and%20alternatives_v4_LR.pdf)

Rios AC, Moufinho CG, Pinto FC, Del Fiol FS, Jozala A, Chaud MV, Vila MM, Teixeira JA4, Balcão VM. Alternatives to overcoming bacterial resistance: State-of-the-art. *Microbiol Res.* 2016 Oct;191:51-80.

Servick, K. Beleaguered phage therapy trial presses on. *Science*. 2016 Jun;352(6293):1506.

Stern AM & Markel H. (2005). The history of vaccines and immunization: familiar patterns, new challenges. *Health Affairs*. 2005 May-Jun;24(3):611-21.

#### **How can we tackle this rather critical situation?**

Baraldi E, Ciabuschi F, Leach R, More CM, Waluszewski A. Exploring the Obstacles to Implementing Economic Mechanisms to Stimulate Antibiotic Research and Development: A Multi-Actor and System-Level Analysis. *AJLM*. 2016 May; 42(2-3):451-486.

Otterson K. New Business Models for Sustainable Antibiotics. Centre on Global Health Security Working Group Papers. 2014 Feb. Available at: <https://www.chathamhouse.org/sites/files/chathamhouse/public/Research/Global%20Health/0214SustainableAntibiotics.pdf>

The White House. National Action Plan for Combating Antibiotic-Resistant Bacteria. 2015 Mar. Available at: [https://obamawhitehouse.archives.gov/sites/default/files/docs/national\\_action\\_plan\\_for\\_combating\\_antibiotic-resistant\\_bacteria.pdf](https://obamawhitehouse.archives.gov/sites/default/files/docs/national_action_plan_for_combating_antibiotic-resistant_bacteria.pdf)

World Health Organization (WHO). Worldwide country situation analysis: response to antimicrobial resistance. 2015 Apr. Available at: [http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf)

Review on Antimicrobial Resistance (AMR Review). Tackling a global health crisis: initial steps. The Review on Antimicrobial Resistance, chaired by Jim O'Neill. 2015 Feb. Available at: <https://amr-review.org/sites/default/files/Report-52.15.pdf>

#### **Access not excess – rational use of antibiotics**

Heyman G, Cars O, Bejarano MT, Peterson S. Access, excess, and ethics – towards a sustainable distribution model for antibiotics. *Ups J Med Sci*. 2014 May;119(2):134-141.

Kalyango JN, Alfven T, Peterson S, Mugenyi K, Karamagi C, Rutebemberwa E. Integrated community case management of malaria and pneumonia increases prompt and appropriate treatment for pneumonia symptoms in children under five years in Eastern Uganda. *Malar J*. 2013 Sep 22;12:340.

Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen JA, Klugman K, Davies S. Access to effective antimicrobials: a worldwide challenge. *Lancet*. 2016 Jan 9;387(10014):168-75.

Médecines Sans Frontières (MSF). Empty gestures: The EU's commitments to safeguard access to medicines. Review of the European Union's Trade & Investment Policy. 2015. Available at: [https://www.msfaaccess.org/sites/default/files/Access\\_HAI-MSF-report\\_2015.pdf](https://www.msfaaccess.org/sites/default/files/Access_HAI-MSF-report_2015.pdf)

Mendelson M, Røttingen JA, Gopinathan U, Hamer DH, Wertheim H, Basnyat B, Butler C, Tomson G, Balasegaram M. Maximising access to achieve appropriate human antimicrobial use in low-income and middle-income countries. *Lancet*. 2016 Jan 9;387(10014):188-98.

So AD, Woodhouse W. Antibiotic Smart Use Initiative in Thailand. Alliance for Health Policy and Systems Research Flagship Report 2014. Available at: [http://www.who.int/alliance-hpsr/resources/FR\\_Ch5\\_Annex3a.pdf](http://www.who.int/alliance-hpsr/resources/FR_Ch5_Annex3a.pdf)